Overview
Centrillion Technologies develops genomics and DNA analysis tools, including sequencing, bioinformatics solutions, and high-density DNA chips designed for large-scale genomic studies. Its offerings combine hardware (ATOM high-throughput detection system), assays (VirusHunter MVP for pathogen detection), and services (sequencing and droplet digital PCR) that work together with sequencing workflows. The company differentiates itself by providing an integrated suite of genomics hardware, assays, and services optimized for big-data analysis and fast, scalable results. Its goal is to enable broad, scalable genomic studies to support drug discovery, personalized medicine, and molecular diagnostics.
Work here?Claim your company
Simplify's take
What believers are saying
- September 2026 site updates show active product marketing and service availability.
- Centrillion’s August 2026 AI messaging targets genome, cell, and tissue data buyers.
- The platform keeps multiple revenue paths: research chips, diagnostics, and sequencing services.
What critics are saying
- VirusHunter MVP remains only through Molecular Vision Laboratories as of August 2026.
- Centrillion shows no fresh 2025-2026 financing, suggesting constrained commercial scale.
- Illumina, Thermo Fisher, and Oxford Nanopore can crush adoption if chip volumes lag.
What makes Centrillion Technologies unique
- Centrillion’s September 2026 chips combine 50,000-2 million variants with sequencing workflows.
- VirusHunter pairs pathogen detection and whole-genome sequencing on ATOM and QuadCore chips.
- The company still owns a rare integrated stack: chips, assays, and clinical-lab services.
Help us improve and share your feedback! Did you find this helpful?